Literature DB >> 15065314

Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients.

D Ferrigno1, G Buccheri.   

Abstract

BACKGROUND: Many factors have prognostic significance in lung cancer. However, their practical value remains controversial except for stage of disease, performance status, and, perhaps, weight loss.
METHODS: In the present study, counts of platelet (P), leukocyte (L), neutrophil (N), and hemoglobin serum content (Hb) were analyzed in 1201 new consecutive lung cancer patients. A set of 28 anthropometric, clinical, physical, laboratory, radiological, and pathological variables was prospectively recorded for all patients. Patients were carefully followed-up, and their subsequent clinical course recorded.
RESULTS: Anemia, leukocytosis, and thrombocytosis were present in 56%, 32%, and 17% of patients, respectively. Correlation tests showed that P was significantly correlated with L, N and Hb (rs = 0.353, 0.352, and -0.295, respectively). Other significant associations were those between Hb and Karnofsky Performance Status (KPS) (rs = 0.232), weight loss (rs = -0.210), and serum protein (rs = 0.263). N and L were correlated with KPS (rs = -0.217 and -0.186), stage of disease (rs = 0.153 and 0.135) and number of metastasis (rs = 0.121 and 0.109). Univariate analyses of survival showed that: a) abnormal values of L were prognosticantly significant in adenocarcinoma (p < 0.0001); b) patients with Hb < 13 g/dL had significantly shorter survivals (p = 0.0002); and c) thrombocytosis was associated to a poor outcome in patients with adenocarcinoma and epidermoid cancers (p = 0.0061 and 0.0072, respectively). The multivariate model selected, in decreasing order of significance, the following variables: 1) stage of disease; 2) KPS; 3) neutrophils; 4) age; and 5) sex.
CONCLUSION: This data indicates that only the leukocyte counts is an independent prognostic factors of survival in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15065314

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  6 in total

1.  Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.

Authors:  Arife Ulas; Ahmet Bilici; Ayse Durnali; Saadet Tokluoglu; Sema Akinci; Kamile Silay; Berna Oksuzoglu; Necati Alkis
Journal:  Tumour Biol       Date:  2015-08-15

2.  Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

Authors:  Georg Holgersson; Martin Sandelin; Even Hoye; Stefan Bergström; Roger Henriksson; Simon Ekman; Jan Nyman; Martin Helsing; Signe Friesland; Margareta Holgersson; Kristina Lamberg Lundström; Christer Janson; Elisabet Birath; Charlotte Mörth; Thomas Blystad; Sven-Börje Ewers; Britta Löden; Michael Bergqvist
Journal:  Med Oncol       Date:  2012-05-08       Impact factor: 3.064

3.  A laboratory prognostic index model for patients with advanced non-small cell lung cancer.

Authors:  Arife Ulas; Fatma Paksoy Turkoz; Kamile Silay; Saadet Tokluoglu; Nilufer Avci; Berna Oksuzoglu; Necati Alkis
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

4.  Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.

Authors:  Andreas Carus; Howard Gurney; Val Gebski; Paul Harnett; Rina Hui; Richard Kefford; Nicholas Wilcken; Morten Ladekarl; Hans von der Maase; Frede Donskov
Journal:  J Transl Med       Date:  2013-08-15       Impact factor: 5.531

5.  Hypercalcemia-leukocytosis syndrome in a patient with cavitating squamous cell carcinoma of the lung.

Authors:  Olga Burzyantseva; Sanath Dharmasena; Suriya Jayawardena; Vijay A Rupanagudi; Padmanabhan Krishnan
Journal:  Cases J       Date:  2009-01-31

6.  Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer.

Authors:  Changyuan Hu; Renpin Chen; Wenjing Chen; Wenyang Pang; Xiangyang Xue; Guangbao Zhu; Xian Shen
Journal:  Exp Ther Med       Date:  2014-04-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.